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Abstract
The biochemical-based Carba NP test has been evaluated to detect carbapenemase-producing Enterobacteriaceae (n = 193) directly from
spiked blood cultures. It was able to rapidly detect KPC (n = 50), IMP (n = 27), VIM (n = 37), NDM (n = 33) and OXA-48-like producers
(n = 46) with sensitivity and speciﬁcity of 97.9% and 100%, respectively. This cost-effective technique may be implemented in any
microbiology laboratory and offers a reliable test for an early identiﬁcation of carbapenemase-producing Enterobacteriaceae directly from
blood culture that could be useful for the management of infected patients.
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Introduction
Since the 2000s, extended spectrum b-lactamase (ESBL) and
acquired cephalosporinase (AmpC) -producing isolates have
been reported worldwide. These isolates are often responsible
for nosocomial infections but during the last 5 years their
dissemination in the community (Escherichia coli) has been
increasingly reported. As these isolates are resistant to almost
all b-lactams with the exception of carbapenems, therapeutic
options are often extremely limited for treating infected
patients and carbapenems have become antibiotics of last
resort [1]. It is therefore of ultimate importance to preserve
now the clinical efﬁcacy of carbapenems (imipenem, ertape-
nem, meropenem, doripenem). However, carbapenem-resis-
tant Enterobacteriaceae are being increasingly reported
worldwide, mostly as a consequence of carbapenemase genes
acquisition [2]. Actually, carbapenem resistance in Enterobac-
teriaceae may be a result of either the association of a decrease
in bacterial outer-membrane permeability with over-expres-
sion of b-lactamases possessing very weak carbapenemase
activity, or the expression of carbapenemases [2–4]. A variety
of carbapenemases has been reported in Enterobacteriaceae
including the Ambler class A b-lactamases of KPC-type, the
metallo-b-lactamases (MBL) (Ambler class B) of VIM-, IMP-,
GIM-, KHM- and NDM-types, and the carbapenem-hydrolysing
class D b-lactamases of the OXA-48-type [2]. Spread of
carbapenemase producers is a critical issue because carbapen-
emases usually confer resistance to most b-lactams. In addition,
those carbapenemase producers are usually associated with
many other non-b-lactam resistance determinants, giving rise
to multidrug- and even pandrug-resistant isolates [5].
Speciﬁc tests may identify carbapenemase activity phenotyp-
ically. The modiﬁed Hodge test based on the in vivo carbape-
nemase production has also been suggested for detecting
carbapenemase producers. This technique is useful to detect
KPC and OXA-48-like producers but may lack speciﬁcity
(high-level AmpC producers) and sensitivity (weak detection of
NDM producers) in several instances [6]. Other detection meth-
ods based on the inhibitory properties of several molecules
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against MBL (e.g. EDTA) or KPC (e.g. boronic acid, clavulanic
acid) producers, may allow discrimination between the diverse
types of carbapenemases [7,8]. Those techniques require
isolation of the bacteria from the infected samples and, at least,
an additional 24-h. Several molecular methods such as simplex
and multiplex PCRs, DNA hybridization and sequencing are
considered as the reference for identiﬁcation of carbapenemase
genes [8,9]. Recently a real-time PCR technique has been used
for detecting KPC producers directly from blood cultures [10].
Although interesting, these molecular-based techniques remain
expensive and require expertise. More recently, mass spec-
trometry-based techniques have been developed to detect
carbapenemase production on bacterial isolates [11–13].
Although these techniques seem promising, they require a
preliminary step of bacterial isolation from the infected samples
because no direct application on the clinical specimen has been
developed yet. In addition, they require mass spectrometry
equipment, which is not currently available in most clinical
microbiology laboratories. Additionally, the UV-spectrophoto-
metric assay has been proposed but is time-consuming and
requires trained personnel [14]. These techniques are mostly
used for research purposes.
Recently, a biochemical test (Carba NP test) based on the
colorimetric detection of carbapenemase production has been
developed to identify carbapenemase producers from isolated
colonies [15]. This Carba NP test has not been evaluated using
directly clinical samples. Therefore, the aim of this study was to
determine the ability of the Carba NP test to detect carbapenem-
ase-producing Enterobacteriaceae directly from positive blood
cultures. This technique used in a routine laboratorymay guide the
ﬁrst-line therapy for treating patients with sepsis [16–19].
Materials and Methods
Strain collection
The panel of strains used for spiking blood cultures included
carbapenemase producers of KPC-type (n = 50) (see Supple-
mentary material, Table S1), VIM-type (n = 37) (see Supple-
mentary material, Table S2), IMP-type (n = 27) (see
Supplementary material, Table S3), NDM-type (n = 33)
(see Supplementary material, Table S4), OXA-48-type
(n = 46) (see Supplementary material, Table S5), and non-
carbapenemase producers (n = 74) (see Supplementary mate-
rial, Table S6). All strains had previously been characterized for
their b-lactamase content at their molecular level.
Blood culture preparation
Detection of carbapenemase producers was attempted from
spiked blood cultures, the positivity of which was assessed using
the BactAlert blood culture system (bioMerieux, Marcy l’Etoile,
France). Blood cultures were made from 10 mL sterile total
human blood inoculated with 1 9 103 CFU of each strain.
The 1 9 103 CFU inoculum was prepared by diluting a 0.5
McFarland suspension (108 CFU/mL) in sterilewater.Then, blood
culture bottles (aerobic and anaerobic bottles without charcoal)
were incubateduntil a positivity of the blood culturewas detected
by the BactAlert system (detection time ranged from 6 to 15 h).
As previously described, the ﬁnal inoculum ranged from 5 9 107
to 5 9 109 CFU/mL using this protocol [20].
Detection of carbapenemase activity from blood culture
using the Carba NP test
Detection of carbapenemase producers from blood cultures
using theCarbaNP test was performed as follows: 20 mL brain–
heart infusion (BHI) supplemented with 0.12 μg/mL imipenem
(ﬁnal concentration) and 70 μg/mL ZnSO4 (ﬁnal concentration)
were inoculated with 20 drops (300 lL) of the positive blood
culture. Inoculated BHI were then incubated in agitation at 37°C
for 3 h. Bacteria were recovered by centrifugation at 4000 g for
15 min. The bacterial pellet was resuspended in 150 lL of
20 mM Tris–HCl lysis buffer (B-PERII, Bacterial Protein Extrac-
tion Reagent, Thermo Scientiﬁc, Pierce, Rockford, IL, USA), and
distributed in Microbead tubes (Ultraclean Microbial DNA
isolation kit Bead Tubes, MO BIO Laboratories, Carlsbad, CA,
USA). Mechanical lysis of bacteria was performed by vigorous
agitation of Microbead tubes using a vortex adapter (MO BIO
Laboratories) for 30 min at room temperature. This bacterial
suspension was centrifuged at 10 000 g at room temperature
for 5 min. Thirty microliters of the supernatant, corresponding
to the enzymatic bacterial suspension, was mixed in a microwell
with 100 lL of (i) a diluted phenol red solution containing
0.1 mM ZnSO4 (Merck Millipore, Guyancourt, France), or (ii) a
diluted phenol red solution containing 0.1 mMZnSO4 and 3 mg/
mL imipenem monohydrate (Sigma-Aldrich, Saint-Quentin Fal-
lavier, France). The diluted phenol red solution used was
prepared by taking 2 mL of a phenol red (Merck Millipore)
solution 0.5% weight/volume to which 16.6 mL distilled water
was added. The pH value was then adjusted to 7.8 by adding
drops of 1 M NaOH. Mixtures of the phenol red ( imipenem)
solutions and the enzymatic suspension being tested were
incubated at 37°C for a maximum of 2 h.
Test results were interpreted by technicians who were
blinded to the identity of the samples.
Results and Discussion
When considering bacteraemia due to carbapenemase pro-
ducers, several studies indicate that treatment schemes
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including combinations of effective antimicrobials lead to a
signiﬁcant decrease in mortality compared with monotherapy
[16–19]. The most commonly used combinations are colistin
and tigecycline together with a carbapenem. As the successful
treatment of bacteraemia depends on prompt administration
of the appropriate antimicrobial agents, we may speculate that
TABLE 1. Results of detection of carbapenemase producers directly from positive spiked blood cultures using the Carba NP test
Carbapenemase types Tested isolates (n)





(%)n % n %
KPC 50 50 100 0 0 100 100
IMP 27 27 100 0 0 100 100
VIM 37 37 100 0 0 100 100
NDM 33 33 100 0 0 100 100
OXA-48-like 46 42 91.3 4 8.7 91.3 100
No carbapenemase 74 0 0 74 100 – –
Total results 97.9 100
n, number of isolates.
–, not determined.
FIG. 1. Strategy for identiﬁcation of carbapenemase producers directly from spiked blood cultures using the Carba NP test.
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the use of the Carba NP test directly from positive blood
cultures may signiﬁcantly improve the outcome of infected
patients by early implementation of such combined antimicro-
bial therapies.
When performed directly on spiked blood cultures, this
protocol of carbapenemase detection using the Carba NP test
allowed the detection of 100% of KPC (n = 50), IMP (n = 27),
VIM (n = 37) and NDM (n = 33) producers, and 91.3% of the
OXA-48 producers (42/46) (Table 1, and see Supplementary
material, Tables S1, S2, S3, S4 and S5). Usually, the time
required for obtaining positive results after the start of the
Carba NP test was 5–30 min for KPC producers, 15–60 min
for MBL producers and 30–60 min for OXA-48 producers.
Negative results were always obtained for carbapenem-
ase-negative strains (see Supplementary material, Table S6).
Overall sensitivity and speciﬁcity of the Carba NP test
performed on positive blood cultures were 97.9% and 100%,
respectively (Table 1). The lower detection sensitivity of
OXA-48 producers compared with the other carbapenemase
types may be due to their lower hydrolysis activity compared
with the other types of carbapenemases.
Recently, real-time PCR was demonstrated to be a reliable
technique for rapid detection of KPC producers directly from
positive blood cultures [10]. This technique may reduce the
time for identiﬁcation of KPC producers in blood cultures.
Compared with this real-time PCR assay, use of the Carba
NP test directly from blood culture has multiple advantages.
First, the Carba NP test could detect any carbapenemase
whereas molecular-based techniques are designed to detect
only one or a few carbapenemase genes. Additionally, the
Carba NP test is inexpensive (no need for expensive
equipment) and could be implemented in low-income coun-
tries that are known to be large reservoirs of carbapenemase
producers.
Using this test, the time for identiﬁcation of a carbape-
nemase producer responsible for a bacteraemia can be
reduced from 24–48 h to 3–5 h (Fig. 1). Consequently, this
Carba NP test-based protocol for detection of carbapenem-
ase producers directly from blood cultures may be very
useful in two main situations: (i) detection of carbapenemase
producers in endemic countries and (ii) in an outbreak
situation when the ﬁrst case of carbapenemase producer has
been identiﬁed.
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